Pembrolizumab-induced polymyalgia rheumatica in two patients with metastatic melanoma.

Published on Mar 1, 2017in Joint Bone Spine3.741
· DOI :10.1016/J.JBSPIN.2016.01.007
Bethsabée Garel1
Estimated H-index: 1
(Paris V: Paris Descartes University),
Nora Kramkimel15
Estimated H-index: 15
(Paris V: Paris Descartes University)
+ 2 AuthorsNicolas Dupin61
Estimated H-index: 61
(Paris V: Paris Descartes University)
Joint Bone Spine - In Press.Proof corrected by the author Available online since mardi 26 avril 2016
📖 Papers frequently viewed together
127 Citations
170 Citations
426 Citations
#1Martina Sanlorenzo (UNITO: University of Turin)H-Index: 18
#2Igor Vujic (UCSF: University of California, San Francisco)H-Index: 17
Last. Susana Ortiz-Urda (UCSF: University of California, San Francisco)H-Index: 20
view all 10 authors...
Importance Immunomodulatory anticancer drugs, such as the anti–programmed death-1 drug pembrolizumab, have shown promising results in trials, and more patients will receive such treatments. Little is known about cutaneous adverse events (AEs) caused by these drugs and their possible correlation with treatment response. Objective To describe the frequency and spectrum of cutaneous AEs linked with pembrolizumab and their possible correlation with treatment response. Design, Setting, and Participan...
268 CitationsSource
#1Antoni Ribas (UCLA: University of California, Los Angeles)H-Index: 143
#2Igor Puzanov (Vandy: Vanderbilt University)H-Index: 72
Last. Adil Daud (UCSF: University of California, San Francisco)H-Index: 74
view all 36 authors...
Summary Background Patients with melanoma that progresses on ipilimumab and, if BRAF V600 mutant-positive, a BRAF or MEK inhibitor or both, have few treatment options. We assessed the efficacy and safety of two pembrolizumab doses versus investigator-choice chemotherapy in patients with ipilimumab-refractory melanoma. Methods We carried out a randomised phase 2 trial of patients aged 18 years or older from 73 hospitals, clinics, and academic medical centres in 12 countries who had confirmed prog...
1,039 CitationsSource
#1Caroline Robert (University of Paris-Sud)H-Index: 127
#2Jacob SchachterH-Index: 46
Last. Antoni Ribas (USYD: University of Sydney)H-Index: 143
view all 22 authors...
Background The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma. Methods In this randomized, controlled, phase 3 study, we assigned 834 patients with advanced melanoma in a 1:1:1 ratio to receive pembrolizumab (at a dose of 10 mg per kilogram of body weight) every 2 weeks or every 3 weeks or four dos...
3,408 CitationsSource
#1Matthew M. K. Chan (USYD: University of Sydney)H-Index: 9
#2Richard F. KeffordH-Index: 100
Last. Nicholas Manolios (USYD: University of Sydney)H-Index: 23
view all 5 authors...
We report the acute onset of polyarticular inflammatory arthritis in 2 patients receiving the immune check-point inhibitor, pembrolizumab (MK-3475), anti-PD1 drug for metastatic melanoma after 14 and 11 months therapy, respectively. The first patient had severe tenosynovitis, synovitis, bone marrow
93 CitationsSource
#1Barbara L. Goldstein (Brigham and Women's Hospital)H-Index: 5
#2Lydia Gedmintas (Brigham and Women's Hospital)H-Index: 7
Last. Derrick J. Todd (Brigham and Women's Hospital)H-Index: 21
view all 3 authors...
130 CitationsSource
#1Suzanne L. Topalian (Johns Hopkins University)H-Index: 99
#2F. Stephen Hodi (Harvard University)H-Index: 126
Last. Mario Sznol (Yale University)H-Index: 81
view all 30 authors...
Background Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1. Methods We enrolled patients with advanced melanoma, non–small-cell lung cancer, castrationresistant prostate cancer, or renal-cell or colorectal cancer to receive anti–PD-1 antibody at a dose of 0.1 to 10.0 mg per kilogram of body weight every 2 weeks. Response was as...
8,402 CitationsSource
#1Bhaskar DasguptaH-Index: 48
#2Marco A. Cimmino (UniGe: University of Genoa)H-Index: 50
Last. Eric L. Matteson (Mayo Clinic)H-Index: 95
view all 42 authors...
The objective of this study was to develop EULAR/ACR classification criteria for polymyalgia rheumatica (PMR). Candidate criteria were evaluated in a 6-month prospective cohort study of 125 patients with new onset PMR and 169 non-PMR comparison subjects with conditions mimicking PMR. A scoring algorithm was developed based on morning stiffness >45 minutes (2 points), hip pain/limited range of motion (1 point), absence of RF and/or ACPA (2 points), and absence of peripheral joint pain (1 point). ...
352 CitationsSource
Cited By22
#2Frank VerhoevenH-Index: 12
Last. Daniel WendlingH-Index: 62
view all 6 authors...
#1Thomas Tingry (University of Lyon)
#2Emmanuel Massy (University of Lyon)
Last. Cyrille B. Confavreux (University of Lyon)H-Index: 19
view all 12 authors...
Resume Les immunotherapies anti-cancereuses modifient considerablement le pronostic et la prise en charge des patients. En monotherapie ou en association, les inhibiteurs de points de controle de la reponse immunitaire (ICI), anti-CTLA-4 et anti-PD-(L)1 notamment, agissent en inhibant l’immunotolerance tumorale des lymphocytes T ou en stimulant leur action contre les cellules cancereuses. Ce changement de cible therapeutique entraine un profil de toxicite inedit avec l’apparition de complication...
#1Toshiyuki KitaH-Index: 15
#2Tomoyuki ArayaH-Index: 7
Last. Kazuo Kasahara (Kanazawa University)H-Index: 28
view all 6 authors...
Abstract A 79-year-old woman was diagnosed with stage IV (cT1aN1M1, OSS) lung adenocarcinoma with bone metastasis of the right femur. She received nivolumab as a third-line treatment. She developed pain in the right shoulder, left wrist, right knee, and waist as well as a low-grade fever and morning stiffness, after five courses of nivolumab. After closer examination, she was diagnosed with polymyalgia rheumatica (PMR) precipitated by an immune-related adverse event. Nivolumab was discontinued, ...
This study aims at reporting 11 cases of carpal tunnel syndrome (CTS) occurring in patients on immunotherapy. The increasing use of immune checkpoint inhibitors in oncodermatology is associated with the appearance of immunologic adverse effects linked to nonspecific stimulation of the immune system. CTS has not been reported in this context. A retrospective multicenter review was performed on CTSs occurring on immunotherapy and confirmed with electroneuromyography. Data were collated from patien...
#1Marie KostineH-Index: 14
#2Axel FinckhH-Index: 54
Last. Thierry SchaeverbekeH-Index: 56
view all 23 authors...
Background Rheumatic and musculoskeletal immune-related adverse events (irAEs) are observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given the recent emergence of these events and the lack of guidance for rheumatologists addressing them, a European League Against Rheumatism task force was convened to harmonise expert opinion regarding their identification and management. Methods First, the group formulated research questions for a systematic literature review....
27 CitationsSource
#1Foteini Angelopoulou (University of Patras)H-Index: 1
#2Dimitrios P. Bogdanos (RMIT: RMIT University)H-Index: 54
Last. Dimitrios Daoussis (University of Patras)H-Index: 22
view all 5 authors...
Immune checkpoint inhibitors (ICI) associate with a wide range of immune-related adverse events (Ir-AE), including musculoskeletal manifestations. We aimed at identifying all studies reporting musculoskeletal Ir-AE. An electronic (Medline, Scopus and Web of Science) search was performed using two sets of key words. The first set consisted of: arthritis, musculoskeletal, polymyalgia rheumatica and myositis. The second set consisted of: anti-PD-1, anti-PD-L1, anti-CTLA-4, ipilimumab, tremelimumab,...
2 CitationsSource
#1Ciro ManzoH-Index: 7
#2Marco Isetta (Central and North West London NHS Foundation Trust)H-Index: 3
Last. Alberto CastagnaH-Index: 12
view all 4 authors...
Background: Polymyalgia Rheumatica (PMR) is one of the most frequent rheumatologic immune-related adverse effects (IRAEs) in cancer patients following therapy with immune checkpoint inhibitors (ICIs). Atypical findings in many patients often lead to diagnosing PMR-like syndromes. Materials and methods: The aim of our research was to review reported diagnoses of PMR and PMR-like syndromes following ICIs therapy, and assess whether they can be redefined as adverse drug reaction (ADR). In line with...
2 CitationsSource
Mechanisms of immune checkpoints and their role in autoimmunity are discussed in the context of immune checkpoint inhibitor (ICI) therapy for cancer. The updated clinical spectrum of immune-related adverse events (irAEs), with an in-depth discussion of rheumatic irAEs, is presented. The relationship between ICI-induced loss of self-tolerance in cancer and the implications for understanding of irAEs, rheumatic irAEs in particular, is overviewed.
#1Tal Gazitt (UW: University of Washington)H-Index: 4
#2Devy Zisman (Rappaport Faculty of Medicine)H-Index: 19
Last. Gregory C. Gardner (UW: University of Washington)H-Index: 12
view all 3 authors...
PURPOSE OF THE REVIEW Polymyalgia rheumatica (PMR) is one of the most common inflammatory rheumatologic condition occurring in older adults. It is characterized by proximal pain and stiffness in the shoulders, neck, and/or pelvic girdle in individuals over 50 years of age along with evidence of an intense systemic inflammatory response. Although the above clinical symptoms are very characteristic for the condition, it can be mimicked by other autoimmune, infectious, malignant, and endocrine diso...